Related Experiment Video

Updated: Oct 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade

L Ruilope1

  • 1Department of Nephrology, Hospital 12 de Octobre, Madrid, Spain.

Blood Pressure. Supplement
|November 4, 2000
PubMed

Insights

Effective blood pressure management in hypertension involves more than just lowering readings. Angiotensin II receptor blockers like candesartan offer significant cardiovascular and renal protection by blocking harmful neurohormonal effects.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hypertension prognosis can be improved by managing blood pressure and suppressing adverse neurohormonal influences.
  • Angiotensin-converting enzyme inhibitors reduce cardiac and renal damage, but other agents are also being studied.

Purpose of the Study:

  • To evaluate the efficacy of angiotensin II type 1 (AT1) receptor blockers in reducing cardiac and renal damage.
  • To assess the specific benefits of candesartan in controlling blood pressure and mitigating angiotensin II effects.

Main Methods:

  • Review of studies on angiotensin II type 1 (AT1) receptor blockers.
  • Analysis of candesartan's binding affinity and duration of action.
  • Evaluation of candesartan cilexetil in combination therapy.

Main Results:

  • Angiotensin II type 1 (AT1) receptor blockers show promise in reducing cardiac and renal damage.
  • Candesartan provides sustained 24-hour blood pressure control and blocks major adverse cardiovascular effects of angiotensin II.
  • Candesartan cilexetil is effective and well-tolerated with hydrochlorothiazide for difficult-to-control hypertension.

Conclusions:

  • Effective hypertension management requires addressing neurohormonal influences alongside blood pressure reduction.
  • Candesartan, an AT1 receptor blocker, offers significant cardiovascular and renal protective benefits.
  • Combination therapy with candesartan cilexetil and hydrochlorothiazide is a viable option for patients needing multiple agents.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...